Business Description
Chordia Therapeutics Inc
ISIN : JP3283730004
Description
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.9 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -42.9 | |||||
| 3-Year EPS without NRI Growth Rate | -57 | |||||
| 3-Year FCF Growth Rate | -58.1 | |||||
| 3-Year Book Growth Rate | 25.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.11 | |||||
| 9-Day RSI | 64.36 | |||||
| 14-Day RSI | 61.57 | |||||
| 6-1 Month Momentum % | 59.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.78 | |||||
| Quick Ratio | 9.78 | |||||
| Cash Ratio | 9.19 | |||||
| Days Payable | 34.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | -7.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -42.19 | |||||
| ROA % | -38.3 | |||||
| ROIC % | -1527.31 | |||||
| ROC (Joel Greenblatt) % | -50255.13 | |||||
| ROCE % | -41.59 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.6 | |||||
| Price-to-Tangible-Book | 5.16 | |||||
| EV-to-EBIT | -9.6 | |||||
| EV-to-EBITDA | -9.61 | |||||
| EV-to-FCF | -8.56 | |||||
| Price-to-Net-Current-Asset-Value | 5.19 | |||||
| Price-to-Net-Cash | 5.56 | |||||
| Earnings Yield (Greenblatt) % | -10.43 | |||||
| FCF Yield % | -8.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chordia Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | |||
| EPS (TTM) (円) | -31.11 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 61.57 | ||
| 14-Day ATR (円) | 25.364858 | ||
| 20-Day SMA (円) | 269 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (円) | 142 - 930 | ||
| Shares Outstanding (Mil) | 68.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chordia Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chordia Therapeutics Inc Stock Events
| Event | Date | Price(円) | ||
|---|---|---|---|---|
| No Event Data | ||||
Chordia Therapeutics Inc Frequently Asked Questions
What is Chordia Therapeutics Inc(TSE:190A)'s stock price today?
The current price of TSE:190A is 円317.00. The 52 week high of TSE:190A is 円930.00 and 52 week low is 円142.00.
When is next earnings date of Chordia Therapeutics Inc(TSE:190A)?
The next earnings date of Chordia Therapeutics Inc(TSE:190A) is .
Does Chordia Therapeutics Inc(TSE:190A) pay dividends? If so, how much?
Chordia Therapeutics Inc(TSE:190A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers